Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Ivacaftor in Cystic Fibrosis With Residual CFTR Function (FEV1 ≥ 40%)
2017-000673-37Phase 2
- Sponsor
- Vertex Pharmaceuticals
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Absolute change from baseline in percent predicted FEV1 after 2 weeks of treatment (Cycle 1 and Cycle 2).
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-000673-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000673-37.